Artificial intelligence is rapidly reshaping drug discovery and development, and the companies making real progress are those that treat AI as an accelerator, not a replacement, for scientific judgement.
Devin Parekh has co-run the heavyweight investment firm Insight Partners for 26 years. Unlike many VCs who are loud on X and seem to live on podcasts, Parekh and Insight Partners tend to lay low.
